CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,021 enrolled
Drug / intervention
aprepitant +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00475085
NCT00475085Phase 3Completed
CompareCT.gov

Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial

Joseph Roscoe·interventional·Posted May 17, 2007·Updated Nov 10, 2015

In Brief

A Phase 3 clinical trial evaluating aprepitant, dexamethasone, and 4 other interventions for Nausea. Completed, enrolled 1,021 participants across 16 sites.

Detailed Summary

RATIONALE: Antiemetic drugs, such as granisetron, dexamethasone, prochlorperazine, aprepitant, and palonosetron, may help lessen or prevent nausea. It is not yet known which combination of antiemetic drugs is more effective in preventing nausea caused by chemotherapy. PURPOSE: This randomized phase III trial is comparing different combinations of granisetron, dexamethasone, prochlorperazine, aprepitant, and palonosetron to see how well they work in preventing nausea in patients undergoing chemotherapy for breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNausea
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 17, 2007
Enrollment StartDec 1, 2006
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 6 yearsPosted 19.1 years ago

Interventions

aprepitantdrug

Given orally or IV

dexamethasonedrug

Given orally or IV

granisetron hydrochloridedrug

Given orally or IV

palonosetron hydrochloridedrug

Given orally or IV

prochlorperazinedrug

Given orally or IV

placebodrug

Given orally